269 related articles for article (PubMed ID: 34203062)
21. A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma.
Xia Y; Li X; Jiang N; Wei X
MedComm (2020); 2023 Dec; 4(6):e424. PubMed ID: 37929016
[TBL] [Abstract][Full Text] [Related]
22. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
Xia B; Qu F; Yuan T; Zhang Y
Oncol Lett; 2015 Dec; 10(6):3339-3344. PubMed ID: 26788133
[TBL] [Abstract][Full Text] [Related]
23. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
24. A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma.
Oriol A
Expert Rev Hematol; 2020 May; 13(5):435-445. PubMed ID: 32182438
[No Abstract] [Full Text] [Related]
25. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
[TBL] [Abstract][Full Text] [Related]
26. Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy.
Du S; Bota D; Kong XT
Neurol Int; 2022 Jun; 14(3):574-580. PubMed ID: 35893281
[TBL] [Abstract][Full Text] [Related]
27. Primary CNS lymphoma: update on molecular pathogenesis and therapy.
Mo SS; Cleveland J; Rubenstein JL
Leuk Lymphoma; 2023 Jan; 64(1):57-65. PubMed ID: 36286546
[TBL] [Abstract][Full Text] [Related]
28. Current targeted therapies in lymphomas.
Chung C
Am J Health Syst Pharm; 2019 Oct; 76(22):1825-1834. PubMed ID: 31580408
[TBL] [Abstract][Full Text] [Related]
29. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
30. Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
O'Kane GM; Leighl NB
CNS Drugs; 2018 Jun; 32(6):527-542. PubMed ID: 29799091
[TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
32. On point in primary CNS lymphoma.
Tsang M; Cleveland J; Rubenstein JL
Hematol Oncol; 2020 Dec; 38(5):640-647. PubMed ID: 32510610
[TBL] [Abstract][Full Text] [Related]
33. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
J Drug Target; 2016; 24(5):373-85. PubMed ID: 26362595
[TBL] [Abstract][Full Text] [Related]
35. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
36. Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma.
Alcantara M; Fuentealba J; Soussain C
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680209
[TBL] [Abstract][Full Text] [Related]
37. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
38. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
39. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
[TBL] [Abstract][Full Text] [Related]
40. Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Gupta E; Accurso J; Sluzevich J; Menke DM; Tun HW
Rare Tumors; 2015 Dec; 7(4):6067. PubMed ID: 26788279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]